Associations - IDH2 mutation

BIOMARKER:

IDH2 mutation

Entrez ID:

3418

Related biomarkers:

Mutation

Others

‹

›

IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	enasidenib Sensitive: A1 - Approval enasidenib Sensitive : A1
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	cytarabine Resistant: B - Late Trials cytarabine Resistant : B
IDH2 mutation IDH2 mutation	Glioma Glioma	temozolomide gel Sensitive: B - Late Trials temozolomide gel Sensitive : B
IDH2 mutation IDH2 mutation	Glioma Glioma	PCV Sensitive: B - Late Trials PCV Sensitive : B
IDH2 mutation IDH2 mutation	Glioma Glioma	BGB-290 Sensitive: C2 – Inclusion Criteria BGB-290 Sensitive : C2
IDH2 mutation IDH2 mutation	Cholangiocarcinoma Cholangiocarcinoma	dasatinib Sensitive: C2 – Inclusion Criteria dasatinib Sensitive : C2
IDH2 mutation IDH2 mutation	Leukemia Leukemia	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
IDH2 mutation IDH2 mutation	Glioma Glioma	TG02 Sensitive: C3 – Early Trials TG02 Sensitive : C3
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine/daunorubicin liposomal formulation Sensitive : C3
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + RO5503781 Sensitive: C3 – Early Trials venetoclax + RO5503781 Sensitive : C3
IDH2 mutation IDH2 mutation	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3
IDH2 mutation IDH2 mutation	Chronic Myelomonocytic Leukemia CMML	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + ABBV-621 Sensitive: C3 – Early Trials venetoclax + ABBV-621 Sensitive : C3
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	CFI-400945 Sensitive: C3 – Early Trials CFI-400945 Sensitive : C3
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + gilteritinib Resistant: C3 – Early Trials venetoclax + gilteritinib Resistant : C3
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + sorafenib Resistant: C3 – Early Trials venetoclax + sorafenib Resistant : C3
IDH2 mutation IDH2 mutation	Glioblastoma GBM	temozolomide gel Sensitive: C3 – Early Trials temozolomide gel Sensitive : C3
IDH2 mutation IDH2 mutation	T Cell Non-Hodgkin Lymphoma T Cell Non-Hodgkin Lymphoma	lenalidomide Resistant: C3 – Early Trials lenalidomide Resistant : C3
IDH2 mutation IDH2 mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	PCV Sensitive: C3 – Early Trials PCV Sensitive : C3
IDH2 mutation IDH2 mutation	Sarcoma Sarcoma	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + enasidenib Sensitive: C4 – Case Studies venetoclax + enasidenib Sensitive : C4
IDH2 mutation IDH2 mutation	Cholangiocarcinoma Cholangiocarcinoma	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES